Diversity and Meta-Analysis of Microbial Differential Abundance in Nasal Metatranscriptomic Profiles of AsthmaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the nasal microbiome differs between people with and without asthma, using meta-transcriptomic (RNA-seq) analysis of two large, independent public datasets. Nasal airway epithelial brushing RNA-seq reads underwent quality control and host read removal, and remaining microbial reads were annotated with Kraken2 (Bracken abundances), followed by alpha and beta diversity analysis, differential abundance analysis with DESeq2 (controlling for age and sex), and a fixed-effects meta-analysis combining the two cohorts.
Who was studied?
Two case-control cohorts were analyzed: GALA II, comprising 694 children of Puerto Rican heritage (441 asthmatic, 253 healthy control; median ages 13.6 and 14.1 years), and CAAPA, comprising 562 individuals of African ancestry (265 asthmatic, 297 control; mean ages 30.0 and 29.0 years). Sequencing was RNA-seq (meta-transcriptomics) from nasal airway epithelium brushings, with taxonomic profiling to the species level.
What were the most important findings?
Asthmatic patients had significantly higher nasal microbiome alpha diversity in GALA II (Shannon median 0.0600 vs 0.0562, Inverse Simpson 1.02 vs 1.01, Fisher 5.92 vs 5.66, and lower Berger-Parker 0.992 vs 0.993, all p < 0.001 or near it), with partial replication in CAAPA (Berger-Parker and Inverse Simpson significant, Shannon and Fisher not). Beta diversity differed significantly by asthma status in GALA II (PERMANOVA) but not in CAAPA (p = 0.265). Differential abundance analysis found 20 species associated with asthma in GALA II (15 enriched, 5 depleted) and 9 in CAAPA (only 1 enriched), with the meta-analysis identifying 11 significant species (7 enriched in asthmatics), and the authors note associations involving Mycobacterium-complex and nontuberculous mycobacterial species.
What are the greatest implications of this study?
The authors conclude that larger, meta-transcriptomic datasets support increased nasal microbiome alpha diversity in asthma and reveal species-level associations, some not previously reported, that may inform asthma pathogenesis and future therapeutic research. Because both datasets are case-control (observational), these are associations rather than causal relationships, and the authors caution that the small absolute differences in diversity and inconsistent beta diversity limit clinical interpretation, calling for prospective and functional studies.